Molecular Mechanisms Through Which Cannabidiol May Affect Skeletal Muscle Metabolism, Inflammation, Tissue Regeneration, and Anabolism: A Narrative Review
Publication: Cannabis and Cannabinoid Research
Volume 7, Issue Number 6
Abstract
Background: Cannabidiol (CBD), a nonintoxicating constituent of the cannabis plant, recently gained a lot of interest among athletes, since it is no longer considered as a prohibited substance by the World Anti-Doping Agency. The increasing prevalence of CBD use among athletes is driven by a perceived improvement in muscle recovery and a reduction in pain. However, compelling evidence from intervention studies is lacking and the precise mechanisms through which CBD may improve muscle recovery remain unknown. This highlights the need for more scientific studies and an evidence-based background. In the current review, the state-of-the-art knowledge on the effects of CBD on skeletal muscle tissue is summarized with special emphasis on the underlying mechanisms and molecular targets. More specifically, the large variety of receptor families that are believed to be involved in CBD's physiological effects are discussed. Furthermore, in vivo and in vitro studies that investigated the actual effects of CBD on skeletal muscle metabolism, inflammation, tissue regeneration, and anabolism are summarized, together with the functional effects of CBD supplementation on muscle recovery in human intervention trials. Overall, CBD was effective to increase the expression of metabolic regulators in muscle of obese mice (e.g., Akt, glycogen synthase kinase-3). CBD treatment in rodents reduced muscle inflammation following eccentric exercise (i.e., nuclear factor kappa B [NF-κB]), in a model of muscle dystrophy (e.g., interleukin-6, tumor necrosis factor alpha) and of obesity (e.g., COX-2, NF-κB). In addition, CBD did not affect in vitro or in vivo muscle anabolism, but improved satellite cell differentiation in dystrophic muscle. In humans, there are some indications that CBD supplementation improved muscle recovery (e.g., creatine kinase) and performance (e.g., squat performance). However, CBD doses were highly variable (between 16.7 and 150 mg) and there are some methodological concerns that should be considered.
Conclusion: CBD has the prospective to become an adequate supplement that may improve muscle recovery. However, this research domain is still in its infancy and future studies addressing the molecular and functional effects of CBD in response to exercise are required to further elucidate the ergogenic potential of CBD.
Get full access to this article
View all available purchase options and get full access to this article.
References
1. Costa B, Colleoni M, Conti S, et al. Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw. Naunyn Schmiedebergs Arch Pharmacol 2004;369(3):294–299;
2. Lafuente H, Pazos MR, Alvarez A, et al. Effects of cannabidiol and hypothermia on short-term brain damage in new-born piglets after acute hypoxia-ischemia. Front Neurosci 2016;10:323;
3. Pazos MR, Mohammed N, Lafuente H, et al. mechanisms of cannabidiol neuroprotection in hypoxic–ischemic newborn pigs: Role of 5HT1A and CB2 receptors. Neuropharmacology 2013;71:282–291;
4. Iannotti FA, Pagano E, Moriello AS, et al. Effects of non-euphoric plant cannabinoids on muscle quality and performance of dystrophic Mdx mice. Br J Pharmacol 2019;176(10):1568–1584;
5. Malfait A, Gallily R, Sumariwalla P, et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 2000;97(17):9561–9566;
6. Weiss L, Zeira M, Reich S, et al. Cannabidiol arrests onset of autoimmune diabetes in NOD mice. Neuropharmacology 2008;54(1):244–249;
7. Weiss L, Zeira M, Reich S, et al. Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity 2006;39(2):143–151;
8. Bielawiec P, Harasim-Symbor E, Sztolsztener K, et al. Attenuation of oxidative stress and inflammatory response by chronic cannabidiol administration is associated with improved N-6/n-3 PUFA ratio in the white and red skeletal muscle in a rat model of high-fat diet-induced obesity. Nutrients 2021;13(5);
9. Fouad AA, Al-Mulhim AS, Jresat I. Cannabidiol treatment ameliorates ischemia/reperfusion renal injury in rats. Life Sci 2012;91(7–8):284–292;
10. Mukhopadhyay P, Rajesh M, Horváth B, et al. Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death. Free Radic Biol Med 2011;50(10):1368–1381;
11. Iffland K, Grotenhermen F. An update on safety and side effects of cannabidiol: A review of clinical data and relevant animal studies. Cannabis Cannabinoid Res 2017;2(1):139–154;
12. Taylor L, Gidal B, Blakey G, et al. A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. CNS Drugs 2018;32(11):1053–1067;
13. U.S. Food and Drug Administration. FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD) | FDA; 2021. Available from: https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd [Last accessed: Febraury 1, 2022]
14. Moltke J, Hindocha C. Reasons for cannabidiol use: A cross-sectional study of CBD users, focusing on self-perceived stress, anxiety, and sleep problems. J Cannabis Res 2021;3(1):5;
15. World Anti-Doping Agency (2022). World Anti-Doping Code International Standard Prohibited List 2022. Montreal Available at: www.wada-ama.org [Last accessed: February 1, 2022]
16. Kasper AM, Sparks SA, Hooks M, et al. High prevalence of cannabidiol use within male professional rugby union and league players: A quest for pain relief and enhanced recovery. Int J Sport Nutr Exerc Metab 2020;30(5):315–322;
17. Beaton L, Allan D, Tarnopolsky M, et al. Contraction-induced muscle damage is unaffected by vitamin E supplementation. Med Sci Sports Exerc 2002;34(5):798–805;
18. Friden J, Sjostrom M, Ekblom B. Myofibrillar damage following intense eccentric exercise in man. Int J Sports Med 1983;4(3):170–176;
19. Peterson J, Trappe T, Mylona E, et al. Ibuprofen and acetaminophen: Effect on muscle inflammation after eccentric exercise. Med Sci Sports Exerc 2003;35(6):892–896;
20. Dáttilo M, Antunes HKM, Galbes NMN, et al. Effects of sleep deprivation on acute skeletal muscle recovery after exercise. Med Sci Sports Exerc 2020;52(2):507–514;
21. Becker L, Totou N, Moura S, et al. Eccentric overload muscle damage is attenuated by a novel angiotensin- (1–7) treatment. Int J Sports Med 2018;39(10):743–748;
22. Caterina MJ, Leffler A, Malmberg AB, et al. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 2000;288(5464):306–313;
23. Camprubí-Robles M, Planells-Cases R, Ferrer-Montiel A. Differential contribution of SNARE-dependent exocytosis to inflammatory potentiation of TRPV1 in nociceptors. FASEB J 2009;23(11):3722–3733;
24. Lotteau S, Ducreux S, Romestaing C, et al. Characterization of functional TRPV1 channels in the sarcoplasmic reticulum of mouse skeletal muscle. PLoS One 2013;8(3):58673;
25. Bisogno T, Hanuš L, De Petrocellis L, et al. Molecular targets for cannabidiol and its synthetic analogues: Effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 2001;134(4):845–852;
26. Iannotti FA, Hill CL, Leo A, et al. Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: Potential for the treatment of neuronal hyperexcitability. ACS Chem Neurosci 2014;5(11):1131–1141;
27. Costa B, Giagnoni G, Franke C, et al. Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. Br J Pharmacol 2004;143(2):247;
28. Costa B, Trovato AE, Comelli F, et al. The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. Eur J Pharmacol 2007;556(1–3):75–83;
29. Xin H, Tanaka H, Yamaguchi M, et al. Vanilloid receptor expressed in the sarcoplasmic reticulum of rat skeletal muscle. Biochem Biophys Res Commun 2005;332(3):756–762;
30. Xu Y, Zhao Y, Gao B. Role of TRPV1 in high temperature-induced mitochondrial biogenesis in skeletal muscle: A mini review. Front Cell Dev Biol 2022;0:756;
31. Vanden Abeele F, Lotteau S, Ducreux S, et al. TRPV1 variants impair intracellular Ca 2+ signaling and may confer susceptibility to malignant hyperthermia. Genet Med 2019;21:441–450;
32. Wu H, Kanatous SB, Thurmond FA, et al. Regulation of mitochondrial biogenesis in skeletal muscle by CaMK. Science 2002;296(5566):349–352;
33. Luo Z, Ma L, Zhao Z, et al. TRPV1 activation improves exercise endurance and energy metabolism through PGC-1α upregulation in mice. Cell Res 2012;22(3):551–564;
34. Ito N, Ruegg UT, Kudo A, et al. Capsaicin mimics mechanical load-induced intracellular signaling events: Involvement of TRPV1-mediated calcium signaling in induction of skeletal muscle hypertrophy. Channels 2013;7(3):221;
35. Ito N, Ichi Takeda S’. Role of Ca 2+ signaling in skeletal muscle hypertrophy and atrophy. J Phys Fit Sport Med 2015;4(2):171–176;
36. Ito N, Ruegg UT, Kudo A, et al. Activation of calcium signaling through Trpv1 by NNOS and peroxynitrite as a key trigger of skeletal muscle hypertrophy. Nat Med 2013;19(1):101–106;
37. Crossland H, Constantin-Teodosiu D, Greenhaff PL. The regulatory roles of PPARs in skeletal muscle fuel metabolism and inflammation: Impact of PPAR agonism on muscle in chronic disease, contraction and sepsis. Int J Mol Sci 2021;22(18);
38. Hou Y, Moreau F, Chadee K. PPARγ is an E3 ligase that induces the degradation of NFκB/P65. Nat Commun 2012;3:1300;
39. Crossland H, Constantin-Teodosiu D, Gardiner SM, et al. Peroxisome proliferator-activated receptor γ agonism attenuates endotoxaemia-induced muscle protein loss and lactate accumulation in rats. Clin Sci 2017;131(13):1437–1447;
40. Esposito G, Scuderi C, Valenza M, et al. Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement. Linden R. ed. PLoS One 2011;6(12):e28668;
41. Bouaboula M, Hilairet S, Marchand J, et al. Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation. Eur J Pharmacol 2005;517(3):174–181;
42. Rockwell CE, Kaminski NE. A cyclooxygenase metabolite of anandamide causes inhibition of interleukin-2 secretion in murine splenocytes. J Pharmacol Exp Ther 2004;311(2):683–690;
43. Lessard SJ, Lo Giudice SL, Lau W, et al. Rosiglitazone enhances glucose tolerance by mechanisms other than reduction of fatty acid accumulation within skeletal muscle. Endocrinology 2004;145(12):5665–5670;
44. Coletta DK, Sriwijitkamol A, Wajcberg E, et al. Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: A randomised trial. Diabetologia 2009;52(4):723–732;
45. Jadoon K, Ratcliffe S, Barrett D, et al. Efficacy and safety of cannabidiol and tetrahydrocannabivarin on glycemic and lipid parameters in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel group pilot study. Diabetes Care 2016;39(10):1777–1786;
46. Kramer HF, Goodyear LJ. Exercise, MAPK, and NF-ΚB signaling in skeletal muscle. J Appl Physiol 2007;103(1):388–395;
47. Balenga NAB, Aflaki E, Kargl J, et al. GPR55 regulates cannabinoid 2 receptor-mediated responses in human neutrophils. Cell Res 2011;21(10):1452–1469;
48. Staton PC, Hatcher JP, Walker DJ, et al. The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain 2008;139(1):225–236;
49. Ryberg E, Larsson N, Sjögren S, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007;152(7):1092–1101;
50. Lin XH, Yuece B, Li YY, et al. A novel CB receptor GPR55 and its ligands are involved in regulation of gut movement in rodents. Neurogastroenterol Motil 2011;23(9);
51. Lanuti M, Talamonti E, Maccarrone M, et al. Activation of GPR55 receptors exacerbates OxLDL-induced lipid accumulation and inflammatory responses, while reducing cholesterol efflux from human macrophages. PLoS One 2015;10(5):e0126839;
52. Lipina C, Walsh SK, Mitchell SE, et al. GPR55 deficiency is associated with increased adiposity and impaired insulin signaling in peripheral metabolic tissues. FASEB J 2019;33(1):1299–1312;
53. Meadows A, Lee JH, Wu CS, et al. Deletion of G-protein-coupled receptor 55 promotes obesity by reducing physical activity. Int J Obes 2016;40(3):417–424;
54. McKillop AM, Moran BM, Abdel-Wahab YHA, et al. Metabolic effects of orally administered small-molecule agonists of GPR55 and GPR119 in multiple low-dose streptozotocin-induced diabetic and incretin-receptor-knockout mice. Diabetologia 2016;59(12):2674–2685;
55. Thiel M, Chouker A, Ohta A, et al. Oxygenation inhibits the physiological tissue-protecting mechanism and thereby exacerbates acute inflammatory lung injury. PLoS Biol 2005;3(6):1088–1100;
56. Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 2001;414(6866):916–920;
57. Sitkovsky MV, Lukashev D, Apasov S, et al. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol 2004;22(D):657–682;
58. Zheng J, Wang R, Zambraski E, et al. Protective roles of adenosine A1, A2A, and A 3 receptors in skeletal muscle ischemia and reperfusion injury. Am J Physiol Hear Circ Physiol 2007;293(6):3685–3691;
59. Carrier EJ, Auchampach JA, Hillard CJ. Inhibition of an equilibrative nucleoside transporter by cannabidiol: A mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci U S A 2006;103(20):7895–7900;
60. Burstein S. Cannabidiol (CBD) and its analogs: A review of their effects on inflammation. Bioorg Med Chem 2015;23(7):1377–1385;
61. Sunda F, Arowolo A. A molecular basis for the anti-inflammatory and anti-fibrosis properties of cannabidiol. FASEB J 2020;34(11):14083–14092;
62. Liou GI, Auchampach JA, Hillard CJ, et al. Mediation of cannabidiol anti-inflammation in the retina by equilibrative nucleoside transporter and A2A adenosine receptor. Invest Ophthalmol Vis Sci 2008;49(12):5526–5531;
63. Ribeiro A, Ferraz-De-Paula V, Pinheiro ML, et al. Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury: Role for the adenosine A2A receptor. Eur J Pharmacol 2012;678(1–3):78–85;
64. Castillo A, Tolón MR, Fernández-Ruiz J, et al. The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB(2) and adenosine receptors. Neurobiol Dis 2010;37(2):434–440;
65. Lynge and Hellsten. Distribution of adenosine A1, A2A and A2B receptors in human skeletal muscle. Acta Physiol Scand 2000;169(4):283–290;
66. Hespel P, Richter EA. Role of adenosine in regulation of carbohydrate metabolism in contracting muscle. Adv Exp Med Biol 1998;441:97–106;
67. Azouzi S, Santuz H, Morandat S, et al. Antioxidant and membrane binding properties of serotonin protect lipids from oxidation. Biophys J 2017;112(9):1863–1873;
68. Russo EB, Burnett A, Hall B, et al. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 2005 308 2005;30(8):1037–1043;
69. Pagano C, Pilon C, Calcagno A, et al. The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. J Clin Endocrinol Metab 2007;92(12):4810–4819;
70. Sarzani R, Bordicchia M, Marcucci P, et al. Altered pattern of cannabinoid type 1 receptor expression in adipose tissue of dysmetabolic and overweight patients. Metabolism 2009;58(3):361–367;
71. Sidibeh CO, Pereira MJ, Lau Börjesson J, et al. Role of cannabinoid receptor 1 in human adipose tissue for lipolysis regulation and insulin resistance. Endocrine 2017;55(3):839–852;
72. Osei-Hyiaman D, DePetrillo M, Pacher P, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005;115(5):1298;
73. Osei-Hyiaman D, Liu J, Zhou L, et al. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest 2008;118(9):3160–3169;
74. Bensaid M, Gary-Bobo M, Esclangon A, et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 MRNA expression in adipose tissue of obese Fa/Fa rats and in cultured adipocyte cells. Mol Pharmacol 2003;63(4):908–914;
75. Dalle S, Koppo K. Cannabinoid receptor 1 expression is higher in muscle of old vs. young males, and increases upon resistance exercise in older adults. Sci Rep 2021;11(1):18349;
76. Dalle S, Schouten M, Meeus G, et al. Molecular networks underlying cannabinoid signaling in skeletal muscle plasticity. J Cell Physiol 2022;237(9):3517–3540;
77. Cavuoto P, McAinch AJ, Hatzinikolas G, et al. The expression of receptors for endocannabinoids in human and rodent skeletal muscle. Biochem Biophys Res Commun 2007;364(1):105–110;
78. Mendizabal-Zubiaga J, Melser S, Bénard G, et al. Cannabinoid CB1 receptors are localized in striated muscle mitochondria and regulate mitochondrial respiration. Front Physiol 2016;7:476;
79. Galiègue S, Mary S, Marchand J, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995;232(1):54–61;
80. Rohbeck E, Eckel J, Romacho T. Cannabinoid receptors in metabolic regulation and diabetes. Physiology 2021;36:102–113;
81. González-Mariscal I, Montoro RA, O'Connel JF, et al. Muscle cannabinoid 1 receptor regulates Il-6 and myostatin expression, governing physical performance and whole-body metabolism. FASEB J 2019;33(5):5850–5863;
82. Ravinet Trillou C, Delgorge C, Menet C, et al. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes 2004;28(4):640–648;
83. Lipina C, Vaanholt LM, Davidova A, et al. CB1 receptor blockade counters age-induced insulin resistance and metabolic dysfunction. Aging Cell 2016;15(2):325–335;
84. Deval C, Capel F, Laillet B, et al. Docosahexaenoic acid-supplementation prior to fasting prevents muscle atrophy in mice. J Cachexia Sarcopenia Muscle 2016;7(5):587–603;
85. Iannotti FA, Pagano E, Guardiola O, et al. Genetic and pharmacological regulation of the endocannabinoid CB1 receptor in duchenne muscular dystrophy. Nat Commun 2018;9(1):1–13;
86. Pekkala S, Wiklund P, Hulmi JJ, et al. Cannabinoid receptor 1 and acute resistance exercise-in vivo and in vitro studies in human skeletal muscle. Peptides 2015;67:55–63;
87. Le Bacquer O, Lanchais K, Combe K, et al. Acute rimonabant treatment promotes protein synthesis in C2C12 myotubes through a CB1-independent mechanism. J Cell Physiol 2021;236(4):2669–2683;
88. Han KH, Lim S, Ryu J, et al. CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages. Cardiovasc Res 2009;84(3):378–386;
89. Haddad M. The Impact of CB1 Receptor on Inflammation in Skeletal Muscle Cells. J Inflamm Res 2021;14:3959–3967;
90. Laprairie RB, Bagher AM, Kelly MEM, et al. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol 2015;172(20):4790–4805;
91. Tham M, Yilmaz O, Alaverdashvili M, et al. Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors. Br J Pharmacol 2019;176(10):1455–1469;
92. Pertwee RG, Ross RA, Craib SJ, et al. (-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. Eur J Pharmacol 2002;456(1–3):99–106;
93. Thomas A, Baillie GL, Phillips AM, et al. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol 2007;150(5):613–623;
94. Zhang M, Jiang SK, Tian ZL, et al. CB2R orchestrates fibrogenesis through regulation of inflammatory response during the repair of skeletal muscle contusion. Int J Clin Exp Pathol 2015;8(4):3491.
95. Yu T, Wang X, Zhao R, et al. Beneficial effects of cannabinoid receptor type 2 (CB2R) in injured skeletal muscle post-contusion. Histol Histopathol 2015;30(6):737–749;
96. Luo XQ, Li A, Yang X, et al. Paeoniflorin exerts neuroprotective effects by modulating the M1/M2 subset polarization of microglia/macrophages in the hippocampal CA1 region of vascular dementia rats via cannabinoid receptor 2. Chin Med 2018;13(1);
97. Braun M, Khan ZT, Khan MB, et al. Selective activation of cannabinoid receptor-2 reduces neuroinflammation after traumatic brain injury via alternative macrophage polarization. Brain Behav Immun 2018;68:224–237;
98. Du Y, Ren P, Wang Q, et al. Cannabinoid 2 receptor attenuates inflammation during skin wound healing by inhibiting M1 macrophages rather than activating M2 macrophages. J Inflamm 2018;15(1):25;
99. Lin L, Yihao T, Zhou F, et al. Inflammatory regulation by driving microglial M2 polarization: neuroprotective effects of cannabinoid receptor-2 activation in intracerebral hemorrhage. Front Immunol 2017;8:112;
100. Jiang P, Wang L, Zhang M, et al. Cannabinoid type 2 receptor manipulates skeletal muscle regeneration partly by regulating macrophage M1/M2 polarization in IR injury in mice. Life Sci 2020;256:117989;
101. Zhang M, Zhang M, Wang L, et al. Activation of cannabinoid type 2 receptor protects skeletal muscle from ischemia-reperfusion injury partly via Nrf2 signaling. Life Sci 2019;230:55–67;
102. Di Marzo V, De Petrocellis L. Why do cannabinoid receptors have more than one endogenous ligand? Philos Trans R Soc B Biol Sci 2012;367(1607):3216;
103. Bielawiec P, Harasim-Symbor E, Konstantynowicz-Nowicka K, et al. Chronic cannabidiol administration attenuates skeletal muscle de novo ceramide synthesis pathway and related metabolic effects in a rat model of high-fat diet-induced obesity. Biomolecules 2020;10(9):1–16;
104. Langer HT, Avey A, Baar K. Cannabidiol does not impact acute anabolic or inflammatory signaling in skeletal muscle in vitro. Cannabis Cannabinoid Res 2022;7(5):628–636;
105. Dalle S, Schouten M, Koppo K. Letter to the Editor: The receptor(s) via which cannabidiol affects muscle signaling: In need for more insights. Cannabis Cannabinoid Res 2022;7(5):717–718;
106. Langer HT, Mossakowski AA, Pathak S, et al. Cannabidiol does not impair anabolic signaling following eccentric contractions in rats. Int J Sport Nutr Exerc Metab 2021;31(2):93–100;
107. Hatchett A, Armstrong K, Hughes B, et al. The influence cannabidiol on delayed onset of muscle soreness. Int J Phys Educ Sport Heal 2020;7(2):89–94.
108. Isenmann E, Veit S, Starke L, et al. Effects of cannabidiol supplementation on skeletal muscle regeneration after intensive resistance training. Nutrients 2021;13(9):3028;
109. Millar SA, Maguire RF, Yates AS, et al. Towards better delivery of cannabidiol (CBD). Pharmaceuticals 2020;13(9):219;
110. Millar SA, Stone NL, Yates AS, et al. A systematic review on the pharmacokinetics of cannabidiol in humans. Front Pharmacol 2018;0(NOV):1365;
111. Cochrane-Snyman K, Cruz C, Morales J, et al. The effects of cannabidiol oil on noninvasive measures of muscle damage in men. Med Sci Sports Exerc 2021;53(7):1460–1472;
112. Araujo Minari AL, Thomatieli-Santos RV. From skeletal muscle damage and regeneration to the hypertrophy induced by exercise: What is the role of different macrophage subsets? Am J Physiol Regul Integr Comp Physiol 2022;322(1):R41–R54;
Cite this article as: Schouten M, Dalle S, Koppo K (2022) Molecular mechanisms via which cannabidiol may affect skeletal muscle metabolism, inflammation, tissue regeneration and anabolism: a narrative review, Cannabis and Cannabinoid Research 7:6, 745–757, doi: 10.1089/can.2022.0220.
Information & Authors
Information
Published In
Cannabis and Cannabinoid Research
Volume 7 • Issue Number 6 • December 2022
Pages: 745 - 757
PubMed: 36454174
Copyright
Copyright 2022, Mary Ann Liebert, Inc., publishers.
History
Published online: 5 December 2022
Published in print: December 2022
Published ahead of print: 28 November 2022
Topics
Authors
Authors' Contributions
M.S., S.D., and K.K. contributed to the conceptualization of the article. M.S. wrote the original draft and S.D. and K.K. reviewed and edited the article. All authors read and approved the final article.
Author Disclosure Statement
No competing financial interests exist.
Funding Information
SD has received a postdoctoral fellowship (grant no. 12Z8622N) from Research Foundation Flanders (FWO).
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Get Access
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.